General Electric
http://www.ge.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From General Electric
Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia
Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.
Coronavirus Update: Vir, WuXi Terminate COVID-19 Antibody Pact
Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.
Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.
Company Information
- Industry
- Diversified
- Medical Devices
- Other Names / Subsidiaries
-
- Amersham
- Clarient Inc.
- Asymptote Limited
- GE Healthcare
- GE Medical Systems LLC
- Monica Healthcare
- Novia Strategies
- Vital Signs.
- Xcellerex
- U-Systems
- Zionexa SAS